Literature DB >> 2090682

Study on hepatotoxicity and other side-effects of antituberculosis drugs.

D P Taneja1, D Kaur.   

Abstract

A prospective study of different side-effects and toxicity of different antituberculosis drugs was made on 125 cases of pulmonary tuberculosis, divided into 3 groups according to the regime of treatment. Group A consisted of 50 patients, taking streptomycin, ethambutol and isoniazid. Group B of 50 patients received streptomycin plus ethambutol plus isoniazid and rifampicin and 25 patients comprising group C received streptomycin plus isoniazid plus ethambutol and pyrazinamide. The group B showed hepatotoxicity in 30% cases, out of which clinical jaundice with abnormal liver function tests being 26% and rest 4% cases were of anicteric hepatitis, while group A showed only 6% hepatotoxicity with 4% clinical jaundice and 2% anicteric hepatitis. In group A out of 50 cases only 2 patients complained of colour blindness, which reversed with the stoppage of drugs. In group C out of 25 cases 3 patients had gouty problems and responded with stoppage of drugs. Patients in group A developed jaundice in a mean of 50 days while those in group B developed jaundice in 17 days.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2090682

Source DB:  PubMed          Journal:  J Indian Med Assoc        ISSN: 0019-5847


  8 in total

1.  Efficacies of liposome-encapsulated streptomycin and ciprofloxacin against Mycobacterium avium-M. intracellulare complex infections in human peripheral blood monocyte/macrophages.

Authors:  S Majumdar; D Flasher; D S Friend; P Nassos; D Yajko; W K Hadley; N Düzgüneş
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

2.  Risk Factors of Hepatotoxicity During Anti-tuberculosis Treatment.

Authors:  A C Anand; A K Seth; M Paul; P Puri
Journal:  Med J Armed Forces India       Date:  2011-07-21

3.  Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study.

Authors:  J N Pande; S P Singh; G C Khilnani; S Khilnani; R K Tandon
Journal:  Thorax       Date:  1996-02       Impact factor: 9.139

4.  Therapeutic efficacy of liposomal rifabutin in a Mycobacterium avium model of infection.

Authors:  M M Gaspar; S Neves; F Portaels; J Pedrosa; M T Silva; M E Cruz
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

5.  Antituberculosis treatment-induced hepatotoxicity: role of predictive factors.

Authors:  J Singh; A Arora; P K Garg; V S Thakur; J N Pande; R K Tandon
Journal:  Postgrad Med J       Date:  1995-06       Impact factor: 2.401

6.  Formulation and efficacy of liposome-encapsulated antibiotics for therapy of intracellular Mycobacterium avium infection.

Authors:  Y K Oh; D E Nix; R M Straubinger
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

Review 7.  Hepatic safety of antibiotics used in primary care.

Authors:  Raúl J Andrade; Paul M Tulkens
Journal:  J Antimicrob Chemother       Date:  2011-05-17       Impact factor: 5.790

8.  Evaluation of anti-tuberculosis induced adverse reactions in hospitalized patients.

Authors:  Kheirollah Gholami; Elahe Kamali; Mahboubeh Hajiabdolbaghi; Gloria Shalviri
Journal:  Pharm Pract (Granada)       Date:  2006
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.